Table 4.
Selected directly acting antiviral agents and host targeting agents whose development has been stopped or temporarily halted[63]
| Drugs name Company Target/Active site | ||
| NS3 /4A protease inhibitors | ||
| Ciluprevir BILN 2061 | Boehringer Ingelheim | Active site/macrocyclic |
| Narlaprevir (SCH900518) | Schering-Plough | Active site/linear |
| PHX1766 | Pheromix | Active site |
| Danoprevir (R7227) | Roche/InterMune | Active site/macrocyclic |
| Faldaprevir (BI201335) | Boehringer Ingelheim | Active site/linear |
| Telaprevir (VX-950) | Vertex | Withdrawn |
| Boceprevir (SCH503034) | Merck | Withdrawn |
| Nucleoside analogue NS5B polymerase inhibitors (NI) | ||
| Valopicitabine (NM283) | Idenix/Novartis | Active site |
| R1626 | Roche | Active site |
| Mericitabine (R7128) | Roche/Pharmasset | Active site |
| GS-938 | Gilead | Active site |
| IDX184 | Idenix | Active site |
| Non-nucleoside NS5B polymerase inhibitors (NNI) | ||
| BILB 1941 | Boehringer Ingelheim | NNI site 1/thumb |
| MK-3281 | Merck | NNI site 1/thumb 1 |
| VX-759 | Vertex | NNI site 2/thumb 2 |
| VX-222 | Vertex | NNI site 2/thumb 2 |
| VX-916 | Vertex | NNI site 2/thumb 2 |
| ABT-072 | AbbVie | NNI site 3/palm 1 |
| HCV-796 | ViroPharma/Wyeth | NNI site 4/palm 2 |
| Filibuvir (PF-00868554) | Pfizer | NNI site 2/thumb 2 |
| IDX375 | Idenix | NNI site 4/palm 2 |
| Tegobuvir (GS-9190) | Gilead | NNI site 4/palm 2 |
| GS-9669 | Gilead | NNI site 3/palm 1 |
| Deleobuvir | Böhringer | NNI site 3/palm 1 |
| Host targeting agents | ||
| NIM811 | Novartis | Cyclophilin inhibitor |
| Alisporivir (Debio-025) | Novartis | Cyclophilin inhibitor |